Drug Approval | March 27, 2023
Briefs: Morepen Laboratories and Zydus Lifesciences
The company is addressing these observations
The company is addressing these observations
The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin’s marketed products worldwide
With the combination of oral solid, inhalation, dermatology, high potent and oral contraceptive products, this is an important facility of the company
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
PM to launch TB-Mukt Panchayat initiative; official pan-India rollout of a shorter TB Preventive Treatment and Family-centric care model for TB
Women of all ages will get round-the-clock access to comprehensive treatment
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
Biocorp will receive an initial milestone payment this year
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
Proposed combination enhances Pfizer’s position as a leading company in oncology
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
